素饮食干预肥胖减肥-一个叙述审查,挑战,和开放的问题
1Nutrition Department, Health Sciences Faculty, Ariel University, Ariel, Israel.
Current nutrition reports
|March 8, 2025
概括
素饮食 (KD) 有效地降低了体重和体脂等肥胖指标,通过体 (KB) 水平监测. 然而,在标准化坚持和保持瘦体质量方面,仍然存在挑战.
科学领域:
- 代谢健康 代谢健康
- 营养科学 营养科学
- 肥胖问题研究研究
背景情况:
- 低饮食 (KD),以碳水化合物限制为特征,模仿禁食并将新陈代谢转向体 (KB) 使用.
- 虽然KD在减肥和代谢综合征方面表现有前途,但它对各种减肥指标的影响仍在争论中.
- 挑战包括监测遵守,定义最佳的宏观营养素比例,并确保长期可持续性.
研究的目的:
- 审查肥胖的KD干预措施的减肥结果.
- 为了评估KD的有效性,使用体 (KB) 作为坚持的指标.
- 确定肥胖管理的KD应用中的挑战和改进领域.
主要方法:
- 对有关肥胖的KD干预措施的当前文献进行系统审查.
- 通过KB水平监测遵守的研究分析.
- 评估体重,体重指数,身体组成和食欲调节的变化.
主要成果:
- 干预KD显著减少体重,BMI,腰围,内脏脂肪组织,脂肪质量和身体脂肪百分比.
- 在没有同时进行抵抗训练的情况下,观察到瘦身量略有下降.
- 在坚持标志物 (KB),碳水化合物摄入量 (7-27%),饮食持续时间 (28天-12个月) 和随访频率方面注意到了变化.
结论:
- 在肥胖患者中,KD干预改善了与体重相关的结果.
- 挑战包括潜在的瘦身量减少没有抵抗运动和不一致的坚持.
- 标准化方法,改进干预措施和建立明确的 KB 遵守标记对于优化 KD 有效性至关重要.
相关概念视频
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...